Contact Us

Depomed Headquarters
7999 Gateway Blvd., Suite 300
Newark, CA 94560
Tel: 510.744.8000
Fax: 510.744.8001

Investor Relations 
investors@depomed.com

Business Development
busdev@depomed.com

Trade
trade@depomed.com

Patient/ Physician Information

Phone Number: 866.458.6389
Email Address: depomed@ashfieldhealthcare.com

NUCYNTA® ER (tapentadol) extended release tablets indicated for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Product website: www.nucynta.com

NUCYNTA® (tapentadol) oral tablets, CII for the management of moderate to severe acute pain in adults
Product website: www.nucynta.com

Gralise® (gabapentin) Tablets, for the management of post-herpetic neuralgia (PHN)
Product website: www.gralise.com

Cambia® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory (NSAID) drug for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older
Product website: www.CambiaRx.com

Lazanda® (fentanyl) nasal spray CII, for the management of breakthrough pain in adults with cancer
Product website: www.lazanda.com

Zipsor® (diclofenac potassium) Liquid filled capsules, for the relief of mild to moderate acute pain in adults
Product website: www.zipsor.com

Key Facts

Headquarters: Newark, CA

Nasdaq symbol: DEPO

Number of employees: Approx. 450

Marketed Products:

NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

NUCYNTA® (tapentadol), an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults

Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN)

Cambia® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory (NSAID) drug for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in adults with cancer

Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain

Development Products

Cenbranopadol, a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain 

Products Marketed By Partners

Glumetza® (metformin hydrochloride extended-release tablets) by Salix

Janumet® XR (sitagliptin/metformin HCl extended-release) tablets by Merck